NCT01817985

A Phase 1 Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment

A Phase 1 Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 33 (actual)
• Sponsor: Gilead Sciences · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Accepted

Summary

This is a Phase 1 Open-Label, Parallel-Group, Single-Dose Study to evaluate the Pharmacokinetics of GS-5816 in subjects with normal hepatic function and moderate or severe hepatic impairment.

Conditions

• Chronic Hepatitis C

Interventions

Type	Name	Description
DRUG	GS-5816

Timeline

• Start date: 2013-03-01
• Primary completion: 2013-08-01
• Completion: 2013-08-01
• First posted: 2013-03-26
• Last updated: 2013-08-29

Locations

6 sites across 2 countries: United States, Puerto Rico